NexGold Mining Corp. (TSXV: NEXG;OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to announce certain potential positive outcomes as it works towards the completion of its Feasibility Study (the ...

– Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial – ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

CNW/ - Denison Mines Corp. ('Denison' or the 'Company') (TSX: DML) (NYSE American: DNN) today filed its Audited Consolidated ...

PRNewswire/ - Denison Mines Corp. ('Denison' or the 'Company') (TSX: DML) (NYSE American: DNN) today filed its Audited Consolidated Financial ...

REHOVOT, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: ...

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...

Welcome to "Silly Season" in the NBA, where we see a lot of instances of teams resting starters to tank for a better draft ...

Coherus BioSciences, Inc. ( NASDAQ: CHRS) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, ...

In June, Moderna and MSD said they may be able to move ahead with regulatory filings for the combination based on progression-free survival (PFS ... in cells that could form the basis of ...